PFE News and Press, Pfizer Inc. From 06/12/24

Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not ...

2024-06-12 13:39:39 ET More on Pfizer Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates Will Boost Revenues Pfizer: Too Early For A Turnaround GSK, Pfizer to appeal...

2024-06-12 12:33:43 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...

2024-06-12 10:55:44 ET More on Alnylam Pharmaceuticals Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentatio...

2024-06-12 03:27:58 ET Summary Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the primary revenue driver today, has shown promising r...

2024-06-11 21:30:00 ET Summary We purchased Maravai shares early in Q3 2023, increased position as stock price dropped, similar to experience with META in 2022. Maravai's subsidiaries, TriLink and Cygnus, play critical roles in NAP and BS segments, with unique assets and capabilit...

2024-06-11 12:08:45 ET Summary Corcept Therapeutics Incorporated share prices were initially suppressed after a court ruling that Teva's generic version of Korlym would not infringe on its patents. However, the company is preparing an NDA for Korlym's successor, which could be app...

2024-06-11 08:37:32 ET Summary Affimed's 06/01/24 update on AFM24 means the company has a second viable commercial asset.  This is why the stock popped after ASCO. Acimtamig's update is due before the end of this month.  If it is positive, the stock should run again for ...

2024-06-11 07:23:55 ET More on GSK GSK plc: Long-Term Cash Cow GSK Breathes New Life Into Asthma Treatment With Depemokimab GSK plc (GSK) Q1 2024 Earnings Call Transcript GSK, SpringWorks end collaboration agreement GSK wins FDA nod to expand label fo...

2024-06-11 05:21:00 ET Billionaire investors generally don't necessarily need dividend income to make ends meet. They buy dividend-paying stocks because they know that companies committed to returning a portion of earnings to shareholders tend to outperform ones that don't. In the first...